Arthritis News and Research

Latest Arthritis News and Research

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011

Study identifies demographic and health related characteristics related to mobility limitation

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and featured in a 2011 issue of the Journal of Gerontology, has identified demographic and health related characteristics that were related to mobility limitation.

15 Nov 2011

Scientists discover promising approaches for treatment of pain

Scientists are discovering promising approaches to treating pain, one of the most common and debilitating neurological complaints, according to research released today at Neuroscience 2011, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Nov 2011

New-onset AF, severe sepsis may increase risk of stroke and mortality in hospital settings

A recent study led by researchers at Boston University School of Medicine (BUSM) shows an increased risk of stroke and mortality among patients diagnosed with severe sepsis and new-onset atrial fibrillation (AF) during hospitalization.

14 Nov 2011

Sleep problems may increase risk of fibromyalgia among women

Researchers from Norway have uncovered an association between sleep problems and increased risk of fibromyalgia in women.

14 Nov 2011

Special supplement examines effects of articular cartilage injury, degeneration in soccer players

More than 300 million play soccer across the globe and while the game is one of fast footwork, two organizations are trying to make sure these athletes stay on their feet. F-d-ration Internationale de Football Association (FIFA) and International Cartilage Repair Society (ICRS) have teamed up on a special supplement of Cartilage (published by SAGE) that examines the effects of articular cartilage injury and degeneration in soccer players.

14 Nov 2011

Inflammatory arthritis or autoimmune disease ruled out as cause for joint pain associated with AIs

Researchers exploring why some women who take a common breast cancer drug develop serious joint pain have eliminated two possible causes: inflammatory arthritis and autoimmune disease.

11 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

Human body better at fighting gum disease when fat cells disappear

Case Western Reserve University School of Dental Medicine researchers found the human body is better at fighting gum disease when fat cells, which trigger inflammation, disappear.

10 Nov 2011

Study: Omega-3 supplements can decrease inflammation, anxiety

A recent study gauging the impact of consuming more fish oil showed a marked reduction both in inflammation and, surprisingly, in anxiety among a cohort of healthy young people.

10 Nov 2011

New genetic approach to treat fibrodysplasia ossificans progressiva

Scientists at Penn's Perelman School of Medicine Center for Research in FOP and Related Disorders have developed a new genetic approach to specifically block the damaged copy of the gene for a rare bone disease, while leaving the normal copy untouched.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Safe disposal of needles, syringes and other sharps

Many people use needles, syringes and lancets—called "sharps"—to manage their medical conditions at home. These conditions include diabetes, allergies, infertility, arthritis, hepatitis, HIV, blood clotting disorders, migraines and cancer.

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma, Inc. today reported financial and operating results for the third quarter ended September 30, 2011.

8 Nov 2011

BioScrip third quarter revenue increases 2.9% to $454.0 million

BioScrip, Inc. today announced 2011 third quarter financial results. Revenue for the three months ended September 30, 2011 was $454.0 million and net income was $0.5 million, or $0.01 per diluted share, including $5.0 million in restructuring charges, severance and other employee costs.

8 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011